ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)

DRUG8 trials

Sponsors

Medac Gesellschaft fuer klinische Spezialprapaerate mbH, University Medical Center Utrecht, University Medical Center Utrecht, Heinrich-Heine-Universitaet Duesseldorf, Centre Hospitalier Regional Universitaire, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Conditions

Acute Myeloid Leukemia (AML)Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteriaKidney Transplant RejectionPatients with myelodysplastic syndrome (MDS)Renal Transplant RejectionSteroid refractory Acute Graft versus host Diseasechronic myelomonocytic leukemia (CMML) or secondary acute myeloid leukemia (sAML) before stem cell transplantationinsufficiency renal

Phase 1

Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML

RecruitingCTIS2024-514688-24-00

Heinrich-Heine-Universitaet Duesseldorfchronic myelomonocytic leukemia (CMML) or secondary acute myeloid leukemia (sAML) before stem cell transplantation, Patients with myelodysplastic syndrome (MDS)

Start: 2023-05-26Target: 38Updated: 2025-10-09

Phase 2

Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)

CompletedNCT04114188

Prof. Dr. Petra ReinkeRenal Transplant Rejection

Start: 2016-12-15End: 2020-12-31Updated: 2021-01-29

A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

RecruitingCTIS2023-503952-28-00

Medac Gesellschaft fuer klinische Spezialprapaerate mbHSteroid refractory Acute Graft versus host Disease

Start: 2023-11-13Target: 54Updated: 2025-05-21

ODORAT : Optimal dose of anti-lymphocyte globulin in kidney transplant recipients with low immunological risk

RecruitingCTIS2024-514792-17-00

Centre Hospitalier Regional Universitaireinsufficiency renal, renal transplant

Start: 2025-06-24Target: 18Updated: 2024-10-30

Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)

Not yet recruitingCTIS2024-520326-11-00

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di BresciaAcute Myeloid Leukemia (AML)

Target: 82Updated: 2025-01-31

Phase 3

A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)

RecruitingCTIS2023-505737-26-00

Medac Gesellschaft fuer klinische Spezialprapaerate mbHSteroid refractory Acute Graft versus host Disease

Start: 2020-07-22Target: 210Updated: 2025-12-18

Phase 4

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

University of KhartoumKidney Transplant Rejection

Start: 2018-03-21End: 2024-03-21Target: 300Updated: 2019-01-03

Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trial (UPSIDE)

RecruitingCTIS2023-505877-34-00

University Medical Center Utrecht, University Medical Center UtrechtDiffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria

Start: 2020-08-18Target: 78Updated: 2024-07-23

Related Papers

Tacrolimus After rATG and Infliximab Induction Immunosuppression—RIMINI Trial

Transplantation2023-08-012 citations